RNA cancer vaccines are at the forefront of next-generation cancer immunotherapy, showcasing significant potential.
While AI offers remarkable efficiency, the pharmaceutical industry must address concerns about “black box” predictions – AI ...
Anixa Biosciences signed a letter of intent with VERDI Solutions to develop AI-powered personalized and off-the-shelf cancer ...
Anixa Biosciences (ANIX) has entered into a letter of intent with Verdi Solutions to develop personalized and off-the-shelf peptide vaccines ...
New biomarker and immune data from the ongoing phase 2 trial with EVX-01 will be presented at the American Association for Cancer Research (AACR) ...
Designed with Evaxion’s AI-Immunology™ platform, EVX-01 is a personalized cancer vaccine currently being evaluated as a treatment for advanced melanoma (skin cancer). Evaxion will present new ...
New biomarker and immune data from the ongoing phase 2 trial with EVX-01 will be presented at the American Association for Cancer ... groundbreaking AI-Immunology platform and vaccine pipeline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results